TREATMENT OF EXPERIMENTAL MOTION SICKNESS IN HUMANS

1946 ◽  
Vol 24e (1) ◽  
pp. 10-22 ◽  
Author(s):  
R. L. Noble

Experiments have been conducted on the production and treatment of motion sickness on human volunteers. Of 369 men tested after treatment by a placebo, 56.6% vomited. Tests were repeated at weekly intervals on 183 susceptible individuals so that 661 tests were performed. Repeat tests on 24 subjects not susceptible after treatment with a placebo showed that 12% were ill when no treatment was given. Ten susceptible subjects were swung through only one-half the usual degree of swinging. Of these eight vomited. This procedure selected persons of marked susceptibility to motion sickness.The consistency of the time of vomiting was determined by 106 tests on 65 susceptible men. In repeated tests after a placebo only eight were 13 min. more than the control test. For assaying drugs a standard procedure was adopted. Susceptible individuals were classed as those who, after taking a placebo, vomited before 30 min. of swinging. A susceptible individual was considered protected if in a test a week later he did not vomit and remained swinging for 13 min. longer than his control time. Improvement was present if a person vomited but the time was 13 min. longer than the control. In no case was swinging less than 30 min.The effect of a number of barbiturates on swing sickness has been determined. The most effective was V-12, ethyl-β-methylallylthiobarbituric acid, when administered in a divided dose of a total of five grains. In this case 78% were protected or improved. With a single dose of three grains 26% were similarly affected. V-17 (allylisoamylbarbituric acid)—two grains, V-16 (dicrotylbarbituric acid)—three grains, V-15 (allyl-sec-butylbarbituric acid)—one grain, V-14 (ethylcrotylthiobarbituric acid)—two grains, V-9 (n-butyl-1-methylallylthiobarbituric acid)—nine grains, and sodium amytal—one grain, showed less or no effect. Hyoscine hydrobromide in single doses of 0.4 and 0.65 mgm. showed 31 and 50% protected or improved respectively. The R.C.N. remedy gave a figure of 58%. After removal of nicotinic acid from the R.C.N. mixture 60% were benefited. Nicotinic acid alone, or pretreatment with thiamin gave no protection.A combination of three grains of V-12 with hyoscine was more effective than when either drug was used alone. With a dose of five grains of V-12 and hyoscine the results were only slightly better (80%) when compared with the same dose of V-12 alone (78%). It is suggested that the most effective form of administration of V-12 may be by divided doses of two and one-half grains twice daily for at least 24 hr. previous to exposure to motion.

PEDIATRICS ◽  
1989 ◽  
Vol 83 (5) ◽  
pp. 694-699
Author(s):  
Barry L. Warshaw ◽  
Leonard C. Hymes

Most current reference sources recommend that initial therapy for minimal lesion nephrotic syndrome consist of prednisone, 60 mg/m2 per 24 hours or 2 mg/kg per 24 hours, given in divided doses, and that this regimen be repeated for each relapse. The need for divided-dose daily-administered prednisone is predicated on anecdotal observations that single-dose daily administration is not effective. Because single-dose daily-administered and reduced-dose daily-administered prednisone has been used to treat this condition for several years, experience with these regimens in nephrotic children was analyzed. Forty-one patients were studied, including 22 treated from the onset of their disease. Of these 22, 17 (77%) responded to single-dose daily-administered prednisone (2 mg/kg); after subsequent biospy, each of the nonresponders proved to have lesions other than minimal change disease. The mean response time with single-dose daily-administered prednisone (9.6 days for treatment of the initial onset of nephrotic syndrome and 11.1 days for treatment of relapses) was comparable to that previously reported with divided-dose regimens. In 14 patients with frequent relapses, a single reduced-dose daily-administered dose of prednisone (0.2 to 1.5 mg/kg/d) successfully induced remissions in 55 of 63 relapse episodes. It is concluded that a single morning dose of prednisone effectively induces remission in children with minimal lesion nephrotic syndrome. Among selected patients with frequent relapses, additional steroid sparing may be achieved by the use of this regimen with reduced doses during treatment of relapses.


1963 ◽  
Vol 1 (8) ◽  
pp. 32-32

Equivert (Pfizer) is a combination of 25 mg of the antihistamine buclizine and 25 mg of nicotinic acid per tablet. The makers claim that the drug is useful in “all vertiginous states whether associated with ageing, arteriosclerosis, streptomycin therapy, labyrinthitis, Meniere s syndrome or related conditions.” For this claim the only evidence is an uncontrolled study (J. C. Scal, Eye, Ear, Nose Thr. Monthly 1959, 38, 738) showing “improvement” in 46 of 50 patients with Meniere s syndrome treated with a similar combination. This is one of the many uncontrolled trials of drugs for the relief of vertigo which ignore the tendency of patients with this symptom to improve spontaneously and unpredictably. Only in the drug treatment of vertigo associated with motion sickness have adequate controlled trials been carried out.


2004 ◽  
Vol 72 (3) ◽  
pp. 227-237
Author(s):  
Nahla S. Barakat ◽  
Nawal M. Khalafallah ◽  
Said A. Khalil

The purpose of this study was to evaluate the bioavailability of locally produced 2.5 mg terbutaline sulphate tablets (brand A ) relative to a reference product, Bricanyl 2.5 mg tablets (brand 6). The study was a single dose 5 mg randomized crossover one in 15 healthy volunteers in the fasting state. Urine was collected at intervals of 24 h. Total terbutaline excreted in urine as unchanged drug and as conjugates (sulphate and glucuronide) was determined by a developed and validated HPLC method. In-vitro characteristics of both brands were similar. Based on percent of the dose excreted in urine, the oral bioavailability ranged from 33.5% to 75.8% for both brands. Statistics were applied to judge bioequivalence according to USP 24 in-vivo bioequivalence guidance. Results indicated that brand A and B were bioequivalent and hence interchangeable in medical practice.


Parasitology ◽  
1995 ◽  
Vol 110 (S1) ◽  
pp. S17-S24 ◽  
Author(s):  
S. N. Chatfield ◽  
M. Roberts ◽  
G. Dougan ◽  
C. Hormaeche ◽  
C. M. A. Khan

SummaryGenetically defined, live attenuatedSalmonellavaccines are proving useful both as oral vaccines against salmonellosis and for the development of multivalent vaccines based on the expression of heterologous antigens in such strains. Several candidate attenuatedS. typhistrains are at present being evaluated as new single dose oral typhoid vaccines in human volunteers. The emergence of such a vaccine will facilitate the development of multivalent vaccines for humans. Many antigens from different infectious organisms have been expressed in attenuatedSalmonella. A focus of this work has been on developing vaccines against parasitic diseases. This review will summarize the efforts that have been made in this area.


2006 ◽  
Vol 46 (5) ◽  
pp. 567-576 ◽  
Author(s):  
Leah M. Hesse ◽  
David J. Greenblatt ◽  
Lisa L. von Moltke ◽  
Michael H. Court

1985 ◽  
Vol 38 (3) ◽  
pp. 459 ◽  
Author(s):  
GB Barlin ◽  
W Tan

A series of new N4-substituted 7-bromo-1,5-naphthyridin-4-amines has been prepared from nicotinic acid through 3-bromo-8-chloro- 1,5- naphthyridine by nucleophilic replacement of the 8-chloro substituent with appropriate amines. Several of these compounds, namely 7-bromo-N- (4′-diethylamino-1′-methylbutyl)-1,5-naphthy-ridin-4-amine (′5-azabromoquine'), 4-(7′-bromo-1′,5′-naphthyridin-4′-ylamino)-2-(diethylamino-methyl)phenol and 7-bromo-N-(2′-diethylaminoethyl)-1,5- naphthyridin-4-amine showed significant antimalarial acivity. Apparent cures were effected when these test chemicals were injected intra-peritoneally in a single dose of 200 mg/kg to mice infected with Plasmodium vinckei vinckei.


2008 ◽  
Vol 85 (10) ◽  
pp. 1391-1399 ◽  
Author(s):  
R Brian Stevens ◽  
David F. Mercer ◽  
Wendy J. Grant ◽  
Alison G. Freifeld ◽  
James T. Lane ◽  
...  

1986 ◽  
Vol 65 (12) ◽  
pp. 1420-1423 ◽  
Author(s):  
M.A.C. Van Oosten ◽  
F.J.W. Notten ◽  
F.H.M. Mikx

Metronidazole concentrations were estimated in four human volunteers after a single dose of 750 mg taken orally. Samples of blood, saliva, and gingival crevice fluid were collected before intake and during the following 24 hours. The concentrations of metronidazole in plasma and saliva were measured by high-performance liquid chromatography (HPLC). The concentrations in gingival fluid were estimated by a capillary agar-diffusion assay. The results of the metronidazole measurements as obtained by both methods were significantly correlated. The peak concentrations of metronidazole in plasma and saliva were in the same range, 8.7-13.8 μ g/mL, and similar concentrations were found in the gingival fluid samples. It is concluded that metronidazole taken orally has similar pharmacokinetics in both saliva and plasma, and that a single oral dose of 750 mg metronidazole leads to a concentration of the drug in the gingival crevice fluid that exceeds the minimal inhibitory concentration for most anaerobic oral micro-organisms.


Sign in / Sign up

Export Citation Format

Share Document